AD 452

Drug Profile

AD 452

Latest Information Update: 29 Jan 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sosei R&D
  • Developer Medicines for Malaria Venture; Sosei R&D; Treague
  • Class Antirheumatics; Disease-modifying antirheumatics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malaria; Rheumatoid arthritis

Most Recent Events

  • 06 Jan 2010 Discontinued - Phase-I for Malaria in United Kingdom (PO)
  • 26 Nov 2008 AD 452 licensed to Treague worldwide
  • 26 Nov 2008 Preclinical trials in Malaria in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top